MedPath

Safety Profiles of Liver Biopsy in Hemodialysis Patients With Chronic Viral Hepatitis Pre-treated With Vasopressin

Not Applicable
Conditions
Chronic Hepatitis C
Chronic Hepatitis B
Biopsy
Hemodialysis
Interventions
Procedure: Percutaneous liver biopsy
Registration Number
NCT00635310
Lead Sponsor
National Taiwan University Hospital
Brief Summary

Percutaneous liver biopsy (PLB) is the gold standard for grading necroinflammation and staging fibrosis in patients with chronic viral hepatitis. Whether the use of 1-deamino-8-D-arginine vasopressin (DDAVP) before PLBs in hemodialysis (HD) patients with chronic viral hepatitis has comparable safety profiles to those with normal renal function (NRF) has not been evaluated in prospective studies.

Detailed Description

Chronic viral hepatitis is common in dialysis patients, with the reported prevalence and annual incidence of 3-80% and 2.9%, respectively. Currently, percutaneous liver biopsy (PLB) remains the gold standard for grading necroinflammation and staging fibrosis in patients with liver diseases. In addition, liver histology can help clinicians determine the eligibility of renal transplantation, prognosis, and necessity of antiviral therapy in dialysis patients with chronic viral hepatitis. In chronic hepatitis patients with normal renal function (NRF), the risks of fatal and non-fatal hemorrhage after liver biopsies for non-malignant diseases were 0.04% and 0.16%, respectively. However, the relative risks of post-biopsy hemorrhage in CHC patients with end-stage renal disease to those with NRF remain disputed.

Deamino-8-D-arginine vasopressin (DDAVP), a synthetic analogue of vasopressin, is a commonly used hemostatic agent to treat uremic bleeding by inducing the release of von Willebrand factor (vWF) and factor VIII from their storage sites in endothelial cells.Previous studies have shown that one dose of 0.3-0.4μg/kg body weight DDAVP infusion for dialysis patients could normalize bleeding time (BT), and prevent surgical and renal biopsy bleeding. Nevertheless, two recent studies showed divergent liver biopsy-related bleeding complication rates (0% and 6%, respectively) in dialysis CHC patients pre-treated with DDAVP. Since most studies evaluating the safety of PLB in CHC patients with dialysis were small and retrospective in nature, and not controlled by the biopsy route, the type of biopsy needle, the use of ultrasound guidance, or the number of passes,further studies are urgently needed to solve this important issue. Thus, we aimed to conducted a large clinical trial to compare the safety profiles of PLB between CHC patients with hemodialysis (HD) who were pretreated with DDAVP and those with NRF by the same biopsy technique.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
3520
Inclusion Criteria
  • Chronic hepatitis C (presence of anti-HCV and serum HCV RNA > 6 months)
  • Chronic hepatitis B (presence of HBsAg > 6 months)
  • Receiving regular hemodialysis or normal renal function (Creatinine < 1.5 x ULN)
  • Receiving percutaneous liver biopsy (PLB)
Read More
Exclusion Criteria
  • Human immunodeficiency virus (HIV) co-infection
  • Unwilling or contraindicated to receive percutaneous liver biopsy (PLB)
  • Receiving liver biopsy without ultrasound (US) guidance or automatic cutting needles
  • Did not receive 2 passes of liver biopsy
  • Inadequate record of post-biopsy complications
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
HD patients with CHC or CHBPercutaneous liver biopsyChronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with hemodialysis (HD), pretreated with DDAVP 0.3 ug/kg body weight infusion 30-60 minutes before percutaneous liver biopsies (PLBs)
Ordinary patients with CHC or CHBPercutaneous liver biopsyChronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with normal renal function (NRF) receiving percutaneous liver biopsies (PLBs)
Primary Outcome Measures
NameTimeMethod
Biopsy-related serious hemorrhage rate by intention-to-treat (ITT) analysis14 days
Secondary Outcome Measures
NameTimeMethod
Biopsy-related serious hemorrhage rate by per-protocol (PP) analysis14 days

Trial Locations

Locations (5)

St. Martin De Porres Hospital

🇨🇳

Chia-Yi, Taiwan

Chiayi Christian Hospital

🇨🇳

Chia-Yi, Taiwan

National Taiwan University Hospital, Yun-Lin Branch

🇨🇳

Douliou, Taiwan

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

Far Eastern Memorial Hospital

🇨🇳

Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath